Monitoring and safety of azathioprine therapy in inflammatory bowel disease

23Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active inflammatory bowel disease. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine. The dose of azathioprine has to be reduced or the therapy has to be discontinued frequently because of drug-induced toxicity. In this review, we discuss monitoring of thiopurines, adverse events, malignant complications and how to use azathioprine safely and usefully.

Cite

CITATION STYLE

APA

Kim, M. J., & Choe, Y. H. (2013). Monitoring and safety of azathioprine therapy in inflammatory bowel disease. Pediatric Gastroenterology, Hepatology and Nutrition, 16(2), 65–70. https://doi.org/10.5223/pghn.2013.16.2.65

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free